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(2.2700.345, p0.0001). IVs satisfied identification conditions individually and
as a group. The increasing multiple medication compliance from 50% to 80% was
associated with the reduction of the average probability of predicted CVD occur-
rence from 0.46 (0.091, p0.0001) to 1.14 (0.042, p0.0001) at the mean level
of covariates. CONCLUSIONS: After controlling for endogeneity bias, compliance
withmultiple medications was significantly associated with a decrease in the CVD
event rate with type II diabetes and comorbid hypertension.
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OBJECTIVES: To study the patterns of discontinuation of ACEI/ARB therapy and to
identify factors associated with discontinuation among post myocardial infarction
(MI) patients enrolled in Medicare.METHODS: This is a retrospective cohort study
utilizing the Medicare 5% national sample claims data for 2006-2007. Medicare
beneficiaries with continuous enrollment in Part A, B, and D in 2006-2007, and who
were hospitalized for an acute MI between January 1 and June 30 of 2006, were
identified using a validated algorithm, requiring a hospitalization episode 3 and
180 days with an ICD-9-CM of 410.x1 as primary or secondary diagnosis. Post-MI
patients with an ACEI/ARB prescription within 90 days of discharge were followed
to study patterns of discontinuation until December 31, 2007. Time to discontinu-
ation was defined as the days from initiation of therapy to a therapy gap of 90
days. Survival curves were constructed using the Kaplan-Meier technique, and
potential predictors of therapy discontinuation, including demographic character-
istics, comorbidities and concomitant medications were estimated using Cox pro-
portional hazards regression. RESULTS: Of the 1,949 subjects in the cohort, 66.1%
were females, 82.9% were Caucasian with a mean age of 78.6 (8.2) years. Approx-
imately, 20% of the patients discontinued therapy within six months and 45%
discontinued within a year. Caucasians were less likely to discontinue therapy as
compared to blacks (HR0.774; [0.638-0.939]; p0.0094). Among the comorbid con-
ditions, dyslipidemia (HR0.734; [0.612-0.880]; p0.0008), cerebrovascular disease
(HR1.124; [0.986-1.281]; p0.0806) and COPD (HR1.154; [1.013-1.316]; p0.0319)
were significant predictors of time to discontinuation. Patients on concomitant
beta-blocker (HR0.771; [0.627-0.949]; p0.0141) and statin (HR0.857; [0.736-
0.999]; p0.0491) therapy were less likely to discontinue ACEI/ARB therapy.
CONCLUSIONS: Many patients initiating ACEI/ARB treatment following MI fail to
consistently remain on therapy as is evident by the high rates of discontinuation
within a year. Several factors including race and comorbidities are potential pre-
dictors of this behavior.
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OBJECTIVES: Numerous guidelines on conduct and reporting of health economic
(HE) evaluations have been developed over several decades differing somewhat in
their objectives, scope and specific recommendations.We systematically reviewed
all accessible HE guidelines to identify commonalities and differences with respect
to type and content of recommendations. METHODS: A systematic search of
PubMed/Medline, the Centre for Reviews and Dissemination, the EQUATOR net-
work, and websites of health technology assessment agencies and health care
coverage decisionmaking bodies comprehensively identified publicly accessible HE
guidelines. Thesewere categorized as jurisdictionalmandatory, jurisdictional non-
mandatory or general guidelines. Data was extracted into a template devised to
capture 30 fields of content. Both qualitative and quantitative analyses were
performed. RESULTS: Seventy-four HE guidelines were obtained: 23 jurisdictional
mandatory, 11 jurisdictional non-mandatory and 40 general. The most common
topics addressed by guidelines were: sensitivity analysis (by 91%), data identifica-
tion (89%), perspective (84%), choice of health outcomes (82%), assumptions (78%),
valuation of resources (77%), types of costs (76%)/resources to include (74%), com-
parators (74%) and modeling (74%). Compared to jurisdictional guidelines, general
guidelines focused on a narrower range of topics (e.g., modeling) and were less
prescriptive. Although there was a level of agreement on many issues, areas of
divergence were identified: study perspective (emphasis on society: 32% of guide-
lines; health care payer: 19%), unrelated costs in life-years gained (inclusion in
base-case or sensitivity analysis recommended by 8%, exclusion by 7%), methods
to value productivity losses (friction cost approach: 12%; human capital approach:
15%; other: 3%), and recommended type of sensitivity analysis (probabilistic: 28%;
deterministic sufficient: 28%). CONCLUSIONS: Available guidelines for HE evalua-
tions are diverse and cover a broad range of methodological and reporting issues.
Except for specific jurisdictional needs and a few controversial issues, however, there
appears to be convergence of HE guidance over time and stability of basic content.
EE2
VALIDATION OF THE UPDATED CHARLSON COMORBIDITY INDEX (CCI) TO
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OBJECTIVES: To validate the recently updated Charlson Comorbidity Index (CCI)
for the prediction of future healthcare utilization for diabetic patients.METHODS:
Administrative claims data were obtained for diabetic patients enrolled continu-
ously for three years in the Department of Defense TRICARE program for retrospec-
tive analysis. The updated and the original CCI scores were calculated using base-
line year data. Linear regression models were used to estimate log-transformed
healthcare expenditures (COST) for one- and two-year post-index periods. Zero-
inflated negative binomial regressionmodels were used to estimate the number of
hospitalizations (HOS) and the number of emergency department visits (ED) for
one- and two-year post-index periods. The outcome variables were then dichoto-
mized (above or below the 90th percentile of COST; 1HOS or none; 1 ED or none)
and estimated using logistic regression models. Adjusted R®, Akaike information
criteria (AIC), and c statistics were assessed to compare the two CCI versions.
RESULTS:A total of 8,704 patientswere included in the study. The study population
had a mean age of 51.0 years (SD: 10.5), and 46.3 percent were male. In the linear
regression models, the updated CCI explained more variance than the original CCI
in one-year COST (adjusted R® 13.0%vs. 11.3%) and two-year COST (adjusted R®
15.7% vs. 13.9%), adjusting for age and sex. The updated CCI was a better predictor
of one- and two-year HOS (AIC 8581, 13821) as well as one- and two-year ED (AIC
 17009, 25200). In the logistic regressionmodels, the updatedCCI performedbetter
in predicting all study outcomes (c 0.619 to 0.754) than the original CCI (c 0.611
to 0.737). CONCLUSIONS: In a population of diabetic patients, the updated CCI
showed improved predictive performance compared to the original CCI. The up-
dated CCI should be validated in other patient populations.
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OBJECTIVES: To evaluate the performance of diagnosis based and prescription
based comorbiditymeasures in predicting total health care expenditure in patients
with dementia. METHODS: This cross-sectional study was conducted using the
household and medical provider component files of Medical Expenditure Panel
Survey (MEPS) data from 2000 to 2003 (panel 5, 6, and 7). Dementia patients were
identified using cccodex and International Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9CM) codes. Total health care expenditure was defined
as the sumof inpatient, outpatient and pharmacy costs. The comorbiditymeasures
evaluated were diagnosis based scales (identified using ICD-9CM codes): D’Hoore’s
adaptation of Charlson comorbidity index (CCI), and Elixhauser comorbidity algo-
rithm; and prescription based scales (identified using national drug codes): Chronic
Disease Score (CDS-1 and CDS-2). The performance of comorbidity measures was
compared using the adjusted R® derived from multiple linear regression models
that included baseline demographic (age, race, sex) socio-economic (income, in-
surance, geographic region), and perceived health status variables. The perfor-
mance of combined diagnoses and prescription-based scores was also compared.
RESULTS: The adjusted R2 of the baseline model was 0.1464. Model performance
after the addition of comorbiditymeasureswas: Elixhauser (0.3326), CDS-2 (0.3427),
Charlson/D’Hoore (0.2184), and CDS-1 (0.2388). The performance of combined di-
agnosis and prescription based measures was: CDS-2/Elixhauser (0.4356), CDS
1/Elixhauser (0.3979), CDS-2/D’Hoore (0.3493) and CDS-1/D’Hoore (0.2573).
CONCLUSIONS: The Elixhauser and CDS-2 comorbidity measures combined had
the highest prediction of health care expenditure in patients with dementia. The
improvement in risk adjustment from the combination of diagnosis and prescrip-
tion based measures indicates that these different types of measures may be cap-
turing different aspects of the construct of comorbidity, constructs other than
comorbidity, or both.
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OBJECTIVES: In an analyses of patients with type 2 diabetes (T2DM) in a large
electronic medical record (EMR) database, small differences were found to be sta-
tistically significant betweenN1162 patientswith liraglutide versus a comparison
cohort due to the comparison group sample size (n274,922). The purpose of this
study is to evaluate a bootstrapping technique to provide robust mean and vari-
ance estimates for comparison patients, thereby helping to address the issue of
being over-powered. METHODS: Study patients were age 18 years with T2DM,
prescribed liraglutide or other antidiabetic drug January 1, 2010 to July 16, 2010 and
with13 months of EMR activity. Bootstrapping was used to provide cohort mean,
standard deviation, and 95% CI estimates for the comparison cohort and were
calculated as the mean of the mean values identified in 1000 random draws with
replacement of 1162 comparison patients. Means (95% CI) were compared for con-
tinuous variables (age, HbA1c and blood pressure [BP]) for liraglutide versus the
overall comparison group and to bootstrap estimates. RESULTS:Of 1162 liraglutide
patients, mean (95% CI) age was 55.5 (54.9, 56.2) years versus 60.9 (60.8, 60.9) years
for all comparison patients and 60.9 (60.1, 61.6) years for comparison patients per
bootstrap estimates (both p0.05). HbA1c was 8.12% (8.00, 8.24) for liraglutide ver-
sus 7.62% (7.61, 7.63) and 7.63% (7.49, 7.76) for all comparison patients and per
bootstrap, respectively (both p0.05). BP was 127.0 (126.1, 127.8)/75.8 (75.3, 76.4)
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